Endocrinology

DKA Knowledge Challenge!

Diabetic ketoacidosis isn’t just an emergency room concern. It can start with subtle signs you might see first in your patients. This quick quiz zeroes in on the key red flags, risk factors, and management essentials of DKA that every PCP should know. Test your knowledge and sharpen your clinical instincts - it could make all the difference.

Click here to participate in survey

Latest News

Dual GLP-1/GLP-2 Agonist Dapiglutide Achieves 11.6% Mean Weight Loss at 28 Weeks in Phase 1b Trial
Dual GLP-1/GLP-2 Agonist Dapiglutide Achieves 11.6% Mean Weight Loss at 28 Weeks in Phase 1b Trial

June 20th 2025

The investigational dual GLP-1/GLP-2 agonist led to 11.6% weight loss over 28 weeks with no lifestyle changes, showing strong safety and tolerability in the trial.

Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose / image credit: ©New Africa/AdobeStock
Coexisting HTN, T2D in US Adults Doubled Over 2 Decades: Daily Dose

June 18th 2025

DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy

June 17th 2025

Novo Nordisk Advances Amycretin SC and Oral into Phase 3 Development for Weight Management /image credit ©Remigiusz Góra/stock.adobe.com
Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity

June 13th 2025

GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose / image credit: ©New Africa/AdobeStock
GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose

June 13th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.